Botulinum Neurotoxin Program

About GigaGen

GigaGen is pioneering a novel class of recombinant polyclonal antibody drugs using its industry-leading single-cell technology platforms. Its pipeline includes a Phase 1 anti-CTLA-4 monoclonal antibody (GIGA-564) for oncology and a Phase 1 recombinant polyclonal (GIGA-2339) for Hepatitis B, alongside significant biodefense contracts. As a Grifols subsidiary, the company combines innovative discovery capabilities with the resources and manufacturing expertise of a global plasma leader, positioning it to advance potent, engineered antibody therapies for complex diseases.

Therapeutic Areas